Kadriu, B
Gold, P W
Luckenbaugh, D A
Lener, M S
Ballard, E D
Niciu, M J
Henter, I D
Park, L T
De Sousa, R T
Yuan, P
Machado-Vieira, R
Zarate, C A
Article History
Received: 13 January 2017
Revised: 16 March 2017
Accepted: 4 April 2017
First Online: 30 May 2017
Conflict of Interest
: CAZ is listed as a co-inventor on a patent for the use of ketamine in major depression and suicidal ideation (2 R,6 R)-hydroxynorketamine, (S)-dehydronorketamine, and other stereoisomeric dehydro and hydroxylated metabolites of (R,S)-ketamine metabolites in the treatment of depression and neuropathic pain. CAZ is listed as co-inventor on a patent application for the use of (2 R,6 R)-hydroxynorketamine and (2 S,6 S)-hydroxynorketamine in the treatment of depression, anxiety, anhedonia, suicidal ideation and post-traumatic stress disorders; he has assigned his patent rights to the US. government but will share a percentage of any royalties that may be received by the government. The remaining authors declare no conflict of interest.